Bernadette Connaughton
Director/Board Member at HALOZYME THERAPEUTICS, INC.
Net worth: 3 M $ as of 2024-04-29
Bernadette Connaughton active positions
| Companies | Position | Start | End |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Director/Board Member | 2018-09-09 | - |
| Independent Dir/Board Member | 2018-09-09 | - | |
| ZEALAND PHARMA A/S | Director/Board Member | 2019-04-03 | - |
| Independent Dir/Board Member | 2019-04-03 | - | |
| EDITAS MEDICINE, INC. | Director/Board Member | 2021-10-25 | - |
| Independent Dir/Board Member | 2021-10-25 | - | |
| Boys & Girls Clubs of New Jersey | Director/Board Member | - | - |
Career history of Bernadette Connaughton
Former positions of Bernadette Connaughton
| Companies | Position | Start | End |
|---|---|---|---|
| SYNEOS HEALTH, INC. | Director/Board Member | 2019-11-11 | 2023-09-27 |
| Independent Dir/Board Member | 2019-11-11 | 2023-09-27 | |
| VISTERRA INC | Director/Board Member | 2015-11-30 | 2018-07-31 |
| Bristol-Myers Squibb Pharma Co. | Corporate Officer/Principal | 2003-12-31 | 2017-09-30 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2003-12-31 | 2016-12-31 |
Training of Bernadette Connaughton
| The Johns Hopkins University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistics
International
| United States | 10 |
| Denmark | 2 |
Operational
| Director/Board Member | 6 |
| Independent Dir/Board Member | 4 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| EDITAS MEDICINE, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Visterra, Inc.
 Visterra, Inc. Pharmaceuticals: MajorHealth Technology Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA. | Health Technology |
Syneos Health, Inc.
 Syneos Health, Inc. BiotechnologyHealth Technology Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. It operates through the Clinical Solutions and Commercial Solutions segments. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. It also offers individual services including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, and consultancy services. The company was founded in 1998 and is headquartered in Morrisville, NC. | Health Technology |
| Boys & Girls Clubs of New Jersey | |
| Bristol-Myers Squibb Pharma Co. |
